- Home
- BGI vs MIRA Comparison
BGI vs MIRA Comparison
Compare BGI & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGI
- MIRA
- Stock Information
- Founded
- BGI 1879
- MIRA 2020
- Country
- BGI Canada
- MIRA United States
- Employees
- BGI N/A
- MIRA N/A
- Industry
- BGI
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- BGI
- MIRA Health Care
- Exchange
- BGI Nasdaq
- MIRA Nasdaq
- Market Cap
- BGI 21.8M
- MIRA 20.5M
- IPO Year
- BGI 2005
- MIRA 2023
- Fundamental
- Price
- BGI $1.29
- MIRA $0.95
- Analyst Decision
- BGI
- MIRA Strong Buy
- Analyst Count
- BGI 0
- MIRA 2
- Target Price
- BGI N/A
- MIRA $14.00
- AVG Volume (30 Days)
- BGI 71.4K
- MIRA 360.9K
- Earning Date
- BGI 11-27-2024
- MIRA 05-12-2025
- Dividend Yield
- BGI N/A
- MIRA N/A
- EPS Growth
- BGI N/A
- MIRA N/A
- EPS
- BGI N/A
- MIRA N/A
- Revenue
- BGI $131,596,265.00
- MIRA N/A
- Revenue This Year
- BGI N/A
- MIRA N/A
- Revenue Next Year
- BGI N/A
- MIRA N/A
- P/E Ratio
- BGI N/A
- MIRA N/A
- Revenue Growth
- BGI 4.01
- MIRA N/A
- 52 Week Low
- BGI $0.93
- MIRA $0.51
- 52 Week High
- BGI $3.42
- MIRA $5.01
- Technical
- Relative Strength Index (RSI)
- BGI 57.94
- MIRA 38.16
- Support Level
- BGI $1.03
- MIRA $1.06
- Resistance Level
- BGI $1.24
- MIRA $1.29
- Average True Range (ATR)
- BGI 0.09
- MIRA 0.11
- MACD
- BGI 0.02
- MIRA -0.02
- Stochastic Oscillator
- BGI 78.79
- MIRA 4.74
About BGI Birks Group Inc.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.